Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
1.150
-0.090 (-7.26%)
At close: Oct 2, 2026, 4:00 PM EDT
1.170
+0.020 (1.74%)
After-hours: Oct 2, 2026, 7:30 PM EDT
Tvardi Therapeutics Employees
Tvardi Therapeutics had 12 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,171,917
Market Cap
15.34M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 12 | 0 | - |
| Dec 31, 2024 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Palatin Technologies | 29 |
| SeaStar Medical Holding | 18 |
| Lipocine | 14 |
| Kiora Pharmaceuticals | 13 |
| NewcelX | 12 |
| Cellectar Biosciences | 11 |
| AEON Biopharma | 8 |
| Allarity Therapeutics | 8 |
TVRD News
- 8 days ago - Tvardi announces publication of preclinical data on STAT3 inhibitor - TheFly
- 8 days ago - New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC) - GlobeNewsWire
- 24 days ago - Tvardi Therapeutics assumed with a Buy at Lucid Capital - TheFly
- 5 weeks ago - Tvardi Therapeutics to Participate in Upcoming Investor Events - GlobeNewsWire
- 6 weeks ago - Tvardi Therapeutics reports Q2 EPS (69c), consensus (63c) - TheFly
- 7 weeks ago - Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 - GlobeNewsWire
- 2 months ago - Tvardi plans 2027 ulcerative colitis trial for oral STAT3 inhibitor TTI-109 - TheFly